Moreover, clinical studies indicate that combining bevacizumab and atezolizumab overcomes ICI resistance by reversing VEGF-induced immunosuppression and enhancing CD8+ tumor-infiltrating lymphocytes (TIL) in tumors. This evidence concerns the gene CD8A and neoplasm.